Artiva Biotherapeutics, Inc.’s (NASDAQ:ARTV) Lock-Up Period To Expire on January 15th

Artiva Biotherapeutics’ (NASDAQ:ARTV) lock-up period will expire on Wednesday, January 15th. Artiva Biotherapeutics had issued 13,920,000 shares in its initial public offering on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on ARTV shares. HC Wainwright started coverage on Artiva Biotherapeutics in a research note on Monday, December 30th. They issued a “buy” rating and a $20.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price target on shares of Artiva Biotherapeutics in a report on Wednesday, November 13th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $21.00.

Artiva Biotherapeutics Price Performance

NASDAQ:ARTV opened at $10.26 on Friday. The company’s fifty day simple moving average is $11.37. Artiva Biotherapeutics has a 52-week low of $9.68 and a 52-week high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.24). Equities research analysts anticipate that Artiva Biotherapeutics will post -4.68 EPS for the current year.

Hedge Funds Weigh In On Artiva Biotherapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets bought a new position in Artiva Biotherapeutics during the third quarter valued at approximately $42,000. MetLife Investment Management LLC bought a new stake in Artiva Biotherapeutics in the third quarter worth $135,000. JPMorgan Chase & Co. purchased a new stake in Artiva Biotherapeutics during the third quarter valued at about $166,000. Barclays PLC bought a new position in shares of Artiva Biotherapeutics during the third quarter valued at about $304,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in shares of Artiva Biotherapeutics in the third quarter worth about $623,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.